Iron contributes to endothelial dysfunction in acute ischemic syndromes.
Chekanov
Valeri S
VS
Nikolaychik
Victor
V
D000208:Acute Disease; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000503:physiopathology; D003676:Deferoxamine / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000096:biosynthesis; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000502:physiology*; D007502:Iron Chelating Agents / Q000494:pharmacology*; D007511:Ischemia / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D008222:Lymphokines / Q000096:biosynthesis; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D013577:Syndrome; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007502:Iron Chelating Agents; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D007501:Iron; D003676:Deferoxamine